LEXICON PHARMACEUTICALS, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $5.46 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-03
- LEXICON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $5.46M, a 657.28% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $5.45M.
- LEXICON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $5.83M.
- LEXICON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $3.89M.
- LEXICON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $15.89M.
- LEXICON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $0.00.
- LEXICON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $0.00.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $5.46M 10-Q · filed 2018-05-03 | $10.91M derived: sum of 2 quarters · filed 2018-05-03 | $16.74M derived: sum of 3 quarters · filed 2018-05-03 | $20.63M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-12-31 | $5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $11.28M derived: sum of 2 quarters · filed 2018-03-01 | $15.17M derived: sum of 3 quarters · filed 2018-03-01 | $15.89M 10-K · filed 2018-03-01 |
| 2017-09-30 | $5.83M 10-Q · filed 2017-11-08 | $9.72M derived: sum of 2 quarters · filed 2017-11-08 | $10.44M 10-Q · filed 2017-11-08 | $10.44M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-06-30 | $3.89M 10-Q · filed 2017-08-01 | $4.61M 10-Q · filed 2017-08-01 | $4.61M derived: sum of 3 quarters · filed 2018-05-03 | $4.61M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-03-31 | $721.00K 10-Q · filed 2018-05-03 | $721.00K derived: sum of 2 quarters · filed 2018-05-03 | $721.00K derived: sum of 3 quarters · filed 2018-05-03 | $721.00K derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | $0.00 derived: sum of 3 quarters · filed 2018-03-01 | $0.00 10-K · filed 2018-03-01 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-01 | $0.00 10-Q · filed 2017-08-01 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |